Epidermolysis Bullosa Dystrophica
Recent clinical, regulatory, research and industry developments relating to this disease.
Systems immunology integrates the complex endotypes of recessive dystrophic epidermolysis bullosa.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q2 2027.
- Q2 2027Phase I/II ex Vivo Gene Therapy Clinical Trial for RDEB Using Autologous Skin Equivalent Grafts Genetically Corrected With a COL7A1-encoding SIN Retroviral Vector
- Q4 2030Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) to Treat Patients Suffering From Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Clinical MilestonesViewHide
- 2026-03-18Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) to Treat Patients Suffering From Recessive Dystrophic Epidermolysis Bullosa (RDEB)Results expected Q4 2030
- 2026-02-12Phase I/II ex Vivo Gene Therapy Clinical Trial for RDEB Using Autologous Skin Equivalent Grafts Genetically Corrected With a COL7A1-encoding SIN Retroviral VectorResults expected Q2 2027
- 2026-01-23Impact of Photodynamic Therapy With Curcumin on Tissue Repair and Quality of Life in Patients With Epidermolysis Bullosa, and Identification of Salivary BiomarkersPrimary completion
- 2025-12-01A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell CarcinomaCompleted
- 2026-03-18ClinicalGenetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) to Treat Patients Suffering From Recessive Dystrophic Epidermolysis Bullosa (RDEB)Results expected Q4 2030
- 2026-02-12ClinicalPhase I/II ex Vivo Gene Therapy Clinical Trial for RDEB Using Autologous Skin Equivalent Grafts Genetically Corrected With a COL7A1-encoding SIN Retroviral VectorResults expected Q2 2027
- 2026-01-23ClinicalImpact of Photodynamic Therapy With Curcumin on Tissue Repair and Quality of Life in Patients With Epidermolysis Bullosa, and Identification of Salivary BiomarkersPrimary completion
- 2025-12-01ClinicalA Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell CarcinomaCompleted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes1
- Epidermolysis Bullosa Dystrophica1
Leading journals1
- Nature communications1
Leading researchers8
- Al-Daccak R1
- Aoudjit F1
- Bataille P1
- Bouaziz JD1
- Bourrat E1
- Chen Q1
- Corneau A1
- Delaroque C1
Affiliations (unnormalised)6
- Boston Childrens Hospital1
- Brest University1
- CHU de Quebec Research Centre1
- Institute for Infectious and Inflammatory Diseases1
- Laboratory of Genetic Skin Diseases1
- National Institute of Health and Medical Research (INSERM) UMRS-976 HIPI1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.